Anavex Life Sciences Corp AVXL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024
-
Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update
-
Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024
-
Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference
-
Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference
Trading Information
- Previous Close Price
- $5.45
- Day Range
- $5.45–5.71
- 52-Week Range
- $3.25–10.45
- Bid/Ask
- $5.60 / $5.67
- Market Cap
- $480.79 Mil
- Volume/Avg
- 517,479 / 966,125
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 40
- Website
- https://www.anavex.com
Comparables
Valuation
|
Metric
|
AVXL
|
APLT
|
CTNM
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.70 | 13.34 | 2.21 |
Price/Sales | — | 2,963.35 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
AVXL
APLT
CTNM
Financial Strength
|
Metric
|
AVXL
|
APLT
|
CTNM
|
|---|---|---|---|
Quick Ratio | 11.95 | 2.21 | 58.48 |
Current Ratio | 12.04 | 2.30 | 58.92 |
Interest Coverage | — | — | — |
Quick Ratio
AVXL
APLT
CTNM
Profitability
|
Metric
|
AVXL
|
APLT
|
CTNM
|
|---|---|---|---|
Return on Assets (Normalized) | −22.21% | −80.98% | −18.15% |
Return on Equity (Normalized) | −24.06% | −319.42% | −871.68% |
Return on Invested Capital (Normalized) | −28.37% | −315.20% | −892.99% |
Return on Assets
AVXL
APLT
CTNM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Qvjldyfsc | Kxp | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Rhrwvpqj | Lbcmdxp | $119.6 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Fyfrgtd | Zsfgb | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xbkcxcxf | Jdjwph | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Lnwmkggw | Jbby | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Gnbbdsh | Hbnh | $28.0 Bil | |||
| Moderna Inc
MRNA
| Zjjwkrcs | Jddf | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Lwxrrjdmr | Kdsb | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Gycxcxcp | Qwvvlqw | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Jmbydhdlqv | Vsbdll | $12.6 Bil |
United States